(Q45090317)

9 December 2017

title

Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice (English)

1 reference

9 December 2017

Sang-Won Lee

1

1 reference

9 December 2017

Kyu-Hyung Park

2

1 reference

9 December 2017

Sungha Park

3

1 reference

9 December 2017

Ji-Hye Kim

4

1 reference

9 December 2017

Sung-Yu Hong

5

1 reference

9 December 2017

Soo-Kon Lee

6

1 reference

9 December 2017

Donghoon Choi

7

1 reference

9 December 2017

Yong-Beom Park

8

1 reference

9 December 2017

publication date

1 July 2013

1 reference

9 December 2017

published in

Arthritis & Rheumatology

1 reference

9 December 2017

volume

65

1 reference

9 December 2017

issue

7

1 reference

9 December 2017

page(s)

1902-1912

1 reference

Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

9 December 2017

cites work

1 reference

Advanced glycation end products: sparking the development of diabetic vascular injury

21 January 2018

1 reference

Understanding RAGE, the receptor for advanced glycation end products

21 January 2018

1 reference

RAGE and cardiovascular disease

21 January 2018

1 reference

HMGB1 and RAGE in inflammation and cancer

21 January 2018

1 reference

Solution structure of the soluble receptor for advanced glycation end products (sRAGE).

21 January 2018

1 reference

S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE)

21 January 2018

1 reference

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

21 January 2018

1 reference

HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-κB pathways.

21 January 2018

1 reference

Pathogenesis of kidney disease in systemic lupus erythematosus

21 January 2018

1 reference

Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.

21 January 2018

1 reference

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

Treatment of proliferative lupus nephritis: a slowly changing landscape

21 January 2018

1 reference

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

21 January 2018

1 reference

Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury

21 January 2018

1 reference

RAGE and the pathogenesis of chronic kidney disease

21 January 2018

1 reference

RAGE: exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes

21 January 2018

1 reference

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism.

21 January 2018

1 reference

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion.

21 January 2018

1 reference

Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models.

21 January 2018

1 reference

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

21 January 2018

1 reference

High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus

21 January 2018

1 reference

Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

21 January 2018

1 reference

RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes

21 January 2018

1 reference

TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE.

21 January 2018

1 reference

IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice

21 January 2018

1 reference

Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies

21 January 2018

1 reference

High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4.

21 January 2018

1 reference

Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis.

21 January 2018

1 reference

Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus

21 January 2018

1 reference

Th subset balance in lupus nephritis

21 January 2018

1 reference

Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells

21 January 2018

1 reference

Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus

21 January 2018

1 reference

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

21 January 2018

1 reference

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.37955

1 reference

9 December 2017

1 reference